IGF1 and breast carcinoma: Preclinical studies have demonstrated that the IGF system plays a role across multiple breast cancer subtypes, with IGF-1 receptor (IGF-IR) signaling identified as a potential therapeutic target; blockade of IGF-IR has been shown to inhibit tumor growth, progression, and metastasis (6–8).